Fast Track Designation for Xilonix for Cachexia

Share this content:

XBiotech announced that the company has been granted Fast Track designation for its anti-cachexia drug, Xilonix. 

Xilonix was shown to stop or reverse cachexia in about a third of all advanced cancer patients treated in a clinical study. Anti-tumor and anti-cachexia effects were seen in many different types of cancer. In patients with advanced colorectal cancer, the reversal of cachexia resulted in a dramatic improvement in life expectancy, with patients that responded to treatment having a median survival of 474 days, vs. a median of 72 days in others.

XBiotech will now launch a pivotal Phase 3 study under the FDA's Fast Track program to treat advanced colorectal cancer patients that are suffering from cachexia. The international study will be a randomized, controlled trial to evaluate overall survival in patients treated with Xilonix. The study's results will be intended to provide the basis for marketing approval.

Xilonix is a first-in-class true human antibody that blocks an inflammatory substance (IL-1α) produced by the body in response to tumor growth. This so-called sterile inflammatory response plays a role in cancer progression and the development of lethal symptoms such as cachexia.

For more information visit

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs